Compare AstraZeneca plc (AZN) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Warner Music Group Corp — how do they compare? AstraZeneca plc trades at $158.47 (market cap $248.14B), while Warner Music Group Corp trades at $25.06 (market cap $13.12B). The key difference: AstraZeneca plc is far larger — about 18.9× Warner Music Group Corp's market cap, and Warner Music Group Corp pays the higher dividend (3.19%). Which is the better fit depends on your goals.
| AZN | WMG | |
|---|---|---|
Market Cap | $248.14B | $13.12B |
Sector | Health | Media |
52-Week High | $209.48 | $34.72 |
52-Week Low | $147.06 | $23.65 |
Enterprise Value | $275.41B | $17.42B |
Dividend Yield | 2.01% | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Warner Music Group (WMG) trades at $24.78, down 6.17% in the past 24 hours, with a bearish technical signal and support near $23. Recent earnings show mixed results, with Q1 and Q2 2026 beats but Q3 and Q4 2025 misses. Revenue grew to $6.71B in 2025, though net income margin declined to 5.44%. Analyst consensus is bullish with 16 buy ratings, citing streaming growth and strategic renewals like the NetEase Cloud Music partnership announced July 16, 2026.
The outlook is cautiously optimistic, with strong analyst support and projected revenue growth to $7.3B in 2026. Risks include execution challenges amid leadership changes, competitive pressures, and market volatility. The current valuation at a P/E of 20.06 may appeal to growth-oriented investors, but near-term price weakness reflects earnings uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
